Uniqure NV is back in the race for a hemophilia B gene therapy.
Leerink analyst Michael Schmidt provides a second-quarter recap for shares of Uniqure NV (NASDAQ:QURE), reiterating an Outperform rating with a $27 price target, …
Uniqure NV (NASDAQ:QURE), a leader in human gene therapy, today announced the appointment of Jonathan Garen as Chief Business Officer. Mr.
Uniqure NV (NASDAQ:QURE), a leader in human gene therapy, announced financial results for the first quarter ending March 31, 2016, and provided a …
uniQure NV (NASDAQ:QURE), a leader in human gene therapy, announced the data from several preclinical research programs focused on the development and validation …
Uniqure NV (NASDAQ:QURE), a leader in human gene therapy, announced audited results for the fourth quarter and year ending December 31, 2015, and …
Uniqure NV (NASDAQ:QURE), a leader in human gene therapy, today announced the publication of preclinical data supporting its proprietary Huntington’s disease gene therapy …
While the iShares Nasdaq Biotechnology (IBB) fell nearly 4% today, biotech companies Dynavax Technologies Corporation (NASDAQ:DVAX) and Uniqure NV (NASDAQ:QURE) climbed sharply higher after presenting …
Chipotle Mexican Grill, Inc. (NYSE:CMG) is falling close to 5% after the company disclosed in a SEC filing that it received a subpoena …
Uniqure NV (NASDAQ: QURE), a leader in human gene therapy, announced preliminary topline results from the low-dose cohort of an ongoing Phase I/II clinical …
